|Bid||1,736.50 x 0|
|Ask||1,737.00 x 0|
|Day's Range||1,709.00 - 1,751.50|
|52 Week Range||1,651.50 - 2,703.00|
|Beta (5Y Monthly)||-0.07|
|PE Ratio (TTM)||11.66|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||0.39 (2.26%)|
|Ex-Dividend Date||Mar 17, 2022|
|1y Target Est||27.37|
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.